Forian Inc (FORA) fair value: what the stock is really worth
We calculate from audited financials what Forian Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Forian Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range $1.75 – $14.04 · fair‑value band $1.25 – $1.97 · the $3.08 price screens above the $1.61 fair value. Dashed = 300-day average. As of Aug 28, 2026.
Forian Inc. provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance. It develops commercial, real-world evidence (RWE), and market access solutions and proprietary data-driven insights.
Show more
Forian Inc. provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance. It develops commercial, real-world evidence (RWE), and market access solutions and proprietary data-driven insights. The company's subscription and services-based solutions serve the life sciences, pharmaceutical services, healthcare payer, and provider and financial services industries. Forian Inc. was founded in 2020 and is headquartered in Newtown, Pennsylvania. Forian Inc. operates as a subsidiary of 2025 Acquisition Company, LLC.
Stock analysis
Forian Inc (FORA) currently trades at $3.08, while our model-based Fair Value estimate is $1.61, implying the stock looks roughly 91.3% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $1.27 per share, and 0 of the 7 models we run sit above the $3.08 price.
Bear case: the Asset-Based group reads lowest at $0.6400, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: $1.25 (bear) to $1.97 (bull), the price of $3.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Forian Inc reported revenue of $30.3M in FY2025 versus $16.9M in FY2021, a compound +15.7%/yr. Reported net income was −$2.9M in FY2025.
Key figures
Market cap $95.8M · P/S ratio 2.26 · EPS (TTM) $−0.0900 · Net margin −9.5% · Return on equity −18.0% · Return on assets (EBIT) −23.8% · Operating margin −50.9% · Revenue (TTM) $30.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades near its 52-week high and 88% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −42% fair-value upside, at −48%, FORA screens richer than that median.
Fair Value models
Bear $1.25Fair Value $1.61Bull $1.97
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest YoY
+50.1%
Revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.6%
Revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+123.3%
’20
’21
’22
’23
’24
’25
Share of sales kept as operating profit (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−914.7% (2020) → −8.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, ten years of growth, then 2 % a year. Compared with the average analyst sales forecast (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.1%
How much the company would have to grow every year for ten years to justify the current price.
Analysts expect (Ø )
n/a
No analyst forecast available.
🟢 Little optimism in the price
The price assumes less growth than the company has delivered so far.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 126 stocks
Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−48% · Below median
Profitability
Return on assets−8% · Bottom 25%
Net margin (TTM)−17% · Below median
Operating margin (TTM)−51% · Bottom 25%
Growth and dividend
Revenue growth−3% · Below median
Balance sheet
Debt / equity0.84× · Highest 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B2.28× · Pricier than median
P/S (TTM)2.26× · Pricier than median
P/FCF23.5× · Pricier than median
PEG0.94× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 2
FUTURE (revenue growth)0· sector 28
PAST (return on equity)0· sector 5
HEALTH (low debt)58· sector 98
DIVIDEND (yield)0· sector 45
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Forian Inc Fair Value". https://www.fairvalue-calculator.com/stock/FORA.US
Frequently asked questions
Is Forian Inc (FORA) overvalued or undervalued?
As of Aug 28, 2026, our model estimates a fair value of $1.61 versus the last price from Aug 14, 2026 of $3.08, about −48% upside (overvalued).
What is the fair value of FORA?
Our model-based fair value for Forian Inc is $1.61 (as of Aug 28, 2026), built from audited fundamentals. Last price (from Aug 14, 2026): $3.08.
What is the quality score of FORA?
Forian Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Forian Inc (FORA)?
Our model-based price target is the fair value of $1.61 (as of Aug 28, 2026) from 7 valuation models. Cautious scenario $1.25, optimistic scenario $1.97. It is a calculation from audited fundamentals, not an analyst target.
What is the Forian Inc stock forecast for 2026?
Our models put fair value at $1.61, about −48% upside versus the last price from Aug 14, 2026 of $3.08 (overvalued). Cautious scenario $1.25, optimistic scenario $1.97. The calculation is refreshed regularly with new filings.
What is the revenue of Forian Inc (FORA)?
Forian Inc reported trailing-twelve-month revenue of about $30.1M (latest available figure, as of Aug 28, 2026).
What growth is priced into Forian Inc (FORA)?
For today's price to be fair in a discounted-cash-flow model, Forian Inc would have to grow free cash flow by +20.1 % per year for ten years (discount rate 12.5 %, then 2 % perpetual growth). Over the last 5 years revenue grew +123.3 % per year. As of Aug 28, 2026.
What discount rate (WACC) does the fair value of FORA use?
Our models discount Forian Inc at 12.5 %: a base by market capitalisation (micro), damped by beta 0.93, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Forian Inc that is +20.1 % per year a year over ten years, using the same discount rate (12.5 %) and the same formula as our fair value.
How much growth has Forian Inc (FORA) delivered so far?
Over the past 5 years revenue at Forian Inc grew +123.3 % a year. The price currently implies +20.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Forian Inc (FORA) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Forian Inc (+20.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Forian Inc (FORA)?
The free-cash-flow yield on the price is 3.01 %: that much free cash flow Forian Inc produces per unit of market value. When it exceeds the discount rate of our models (12.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Forian Inc (FORA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Forian Inc it is $1.61 per share (as of Aug 28, 2026), against a price of $3.08. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Forian Inc stock overvalued or undervalued in 2026?
As of Aug 28, 2026, FORA trades above its calculated fair value: price $3.08, fair value $1.61, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FORA?
No. The price is what the market pays today ($3.08); the fair value is what the company's own numbers justify ($1.61). For Forian Inc the two are $1.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Forian Inc worth?
The market values Forian Inc at about $95.8M (market capitalisation, as of Aug 28, 2026). Per share that is $3.08; our models calculate a fair value of $1.61 per share.
What do the bullish and bearish scenarios say about FORA?
Our models span a range for Forian Inc: cautious scenario $1.25, base $1.61, optimistic $1.97 per share (as of Aug 28, 2026, price $3.08). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of FORA?
The PEG ratio of Forian Inc is 0.94 (P/E divided by earnings growth, as of Aug 28, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Forian Inc (FORA)?
Balance-sheet figures for Forian Inc (as of Aug 28, 2026): return on equity −18.0%, debt of 0.84 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is FORA from its 52-week high?
Forian Inc trades at $3.08, about 5% below its 52-week high of $2.94 and 88% above the low of $1.64 (as of Aug 28, 2026). Distance from the high says nothing about value: that is what the fair value of $1.61 is for.
Which stocks are comparable to Forian Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Forian Inc stock attractive at the current price?
The data as of Aug 28, 2026: price $3.08, calculated fair value $1.61 (−48%), Quality Score 60/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FORA calculated?
We run Forian Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.61, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.0 % above its aggregate fair value. Forian Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Forian Inc right now?
The price sits above even our optimistic bull case ($1.97). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Forian Inc
How large is the market capitalisation of Forian Inc (FORA)?
The market capitalisation of Forian Inc is $95.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Forian Inc (FORA)?
The price-to-sales ratio of Forian Inc is 2.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Forian Inc (FORA)?
Earnings per share at Forian Inc are $−0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Forian Inc (FORA)?
The net margin of Forian Inc is −9.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Forian Inc (FORA)?
The return on equity (ROE) of Forian Inc is −18.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Forian Inc (FORA)?
On an EBIT basis the return on assets of Forian Inc is −23.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Forian Inc (FORA)?
The operating margin of Forian Inc is −50.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Forian Inc (FORA)?
Revenue at Forian Inc is growing −2.9% versus a year earlier (3y avg +22.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Forian Inc (FORA)?
Earnings per share at Forian Inc are growing −89.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Forian Inc (FORA) hold?
Forian Inc holds more cash than debt, $12.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Forian Inc in the live analysis
One click puts Forian Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Aug 28, 2026